Syndax Pharmaceuticals Inc.

180 articles with Syndax Pharmaceuticals Inc.

• Syndax Pharmaceuticals Announces Presentations at the 2018 American Society of Clinical Oncology Annual Meeting

  4/27/2018

  Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced five poster presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2018 in Chicago, Illinois.

• Syndax Pharmaceuticals Reports Fourth Quarter 2017 Financial Results and Provides Clinical and Business Update

  3/5/2018

  Phase 2 ENCORE 601 PD-(L)1 refractory melanoma cohort data and melanoma registration strategy disclosure forthcoming in 2Q18; ENCORE 601 PD-(L)1 refractory NSCLC cohort data expected 2Q18; Initial data on MSS-CRC cohort of ENCORE 601 to drive decision on advancement into second stage expected in 2Q18; Company to host conference call today at 4:30 p.m. ET

• Syndax Announces Presentations at the 2018 American Association for Cancer Research Annual Meeting

  2/22/2018

  Syndax Pharmaceuticals, Inc. today announced eight presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting

• Syndax Announces Immuno-Oncology Clinical Trial Collaboration With AstraZeneca

  2/1/2018

  Under the terms of the agreement, Syndax and Astra will collaborate on a non-exclusive basis to evaluate the combination of the two drugs in multiple solid tumor types.

• 

  Genentech Sets Up New Program for New Combo R&D Deal With Syndax

  1/11/2018

  The trial will assess the efficacy, safety, and pharmacokinetics of immunotherapy combination in HR+, HER2- metastatic breast cancer.

• Syndax Pharma Announces Presentation of Data from Immuno-oncology Clinical Trials at the Society for Immunotherapy of Cancer 32nd Annual Scientific Meeting

  11/13/2017

  Syndax Pharma today announced results from the NSCLC and melanoma cohorts of ENCORE 601, an open-label, Phase Ib/II clinical trial employing a Simon two-stage design to evaluate the combination of entinostat plus Merck's anti-PD-1 therapy, KEYTRUDA.

• Syndax Pharma Reports Third Quarter 2017 Financial Results and Provides Clinical and Business Update

  11/8/2017

  As of September 30, 2017, Syndax had $120.6M in cash, cash equivalents and short-term investments.

• Syndax to Announce Third Quarter 2017 Financial Results and Host Conference Call and Webcast on November 7, 2017

  10/31/2017

  Syndax announced today that it will release its third quarter 2017 financial results on Tuesday, November 7, 2017, after the close of the U.S. financial markets.

• Syndax Expands Pipeline with Exclusive Worldwide License to Allergan's Portfolio of Menin-MLL Inhibitors

  10/17/2017

  Syndax today announced that it has entered into an exclusive worldwide license agreement with Vitae Pharma for a portfolio of preclinical, orally-available small molecule inhibitors of the interaction of Menin with the MLL protein.

• Syndax Announces $25 Million Registered Direct Offering of Common Stock

  10/17/2017

  Syndax today announced that it has agreed to sell 2,021,018 shares of its common stock to BVF in a registered direct offering.

• Syndax Announces Dosing Of First Patient In Pivotal Trial Of Entinostat For The Treatment Of Advanced Or Recurrent Breast Cancer In Japan By Partner Kyowa Hakko Kirin

  10/5/2017

• Syndax Announces Updated Presentation Time At The Cantor Fitzgerald Global Healthcare Conference

  9/20/2017

• Syndax Announces Participation At Three Upcoming Investor Conferences

  8/30/2017

• Syndax Reports Second Quarter 2017 Financial Results And Provides Clinical And Business Update

  8/11/2017

• Syndax To Announce Second Quarter 2017 Financial Results And Host Conference Call And Webcast On August 10, 2017

  8/3/2017

• Syndax Release: Preclinical Results Support Entinostat's Role In Targeting The Tumor Microenvironment To Enhance Immune Checkpoint Therapy

  7/12/2017

• Syndax Prices Public Offering Of Common Stock

  5/25/2017

• Syndax Announces Proposed Public Offering Of Common Stock

  5/24/2017

• Syndax Announces Results From Phase II ENCORE 601 Trial Of Entinostat In Combination With KEYTRUDA (Pembrolizumab) For The Treatment Of Advanced Melanoma

  5/18/2017

• Syndax Announces Advancement Of ENCORE 601 In Non-Small Cell Lung Cancer Patients With Disease Progression On Or After PD-1 Therapies

  5/17/2017